We found strong synergistic effects between ABCC1 inhibition and the BH3-mimetics Venetoclax, Navitoclax (BCL-2/BCL-xL inhibitor) and ABT-737 (BCL-2/BCL-xL/BCL-w inhibitor) in different AML cell lines (Fig. 2D and Supplementary Fig. 2B–E). This evidence concerns the gene BCL2L1 and acute myeloid leukemia.